“Rules of the Lombardy HTA commission” has been published

26

Feb 2020

The General Director of Lombardy Healthcare released a decree no. 916 of 29.1.2020. In the first half of February 2020, it was published on the website of the regional HTA program of the Lombardy region.

The decree contains several important notices:

  • Implements the content of the Agreement made by the State-Regions conference, concerning the Strategic Document for the Health Technology Assessment of medical devices, which contains indications for the National HTA Medical Devices Program (Annex 1 of this decree)
  • Approves the document "Assessment path of the appropriateness of use of biomedical devices, large equipment, and diagnostic-therapeutic technologies" (Annex 2 of this decree)
  • It establishes the composition of the regional HTA commission, which must consist of 16 experts from various fields (included head pharmacists, head physicians, head clinical engineers, a health economic experts, and others, all of which must be actively performing their jobs in the Lombard healthcare network)
  • It gives the task to the General Director of Lombardy Healthcare to arrange HTA meetings regularly in the next 3-year-period, and to ensure the set goals (diffusing the most efficient technologies in compliance with the provision of Essential Assistance Levels)
  • It gives the task to the General Director of Lombardy Healthcare to:
    • Nominate Lombardy Healthcare as a collaborative center of the National HTA Program for Medical Devices
    • Collaborate with the steering committee of the above-mentioned program (Cabina di Regia) and the Ministry of Health
    • Maintain the relationships with other stakeholders involved in the HTA process
  • Announces the collaboration with the ASST Niguarda hospital, for the purpose of the implementation of the regional and the National HTA Medical Devices Program
  • To ensure that the output of the HTA work is being used systematically in all areas of procurement by the regional “Innovation and Procurement Company (ARIA),” other regional or hospital-based procurement decision-makers

All the details about the above-mentioned points can be seen in the decree itself, in Italian, here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more